129 related articles for article (PubMed ID: 34999590)
41. Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system.
Ashley L; Jones H; Thomas J; Newsham A; Downing A; Morris E; Brown J; Velikova G; Forman D; Wright P
J Med Internet Res; 2013 Oct; 15(10):e230. PubMed ID: 24161667
[TBL] [Abstract][Full Text] [Related]
42. The Support, Education, and Advocacy (SEA) Program of Care for Women With Metastatic Breast Cancer: A Nurse-Led Palliative Care Demonstration Program.
Reiser V; Rosenzweig M; Welsh A; Ren D; Usher B
Am J Hosp Palliat Care; 2019 Oct; 36(10):864-870. PubMed ID: 30974954
[TBL] [Abstract][Full Text] [Related]
43. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Mueller V; Wardley A; Paplomata E; Hamilton E; Zelnak A; Fehrenbacher L; Jakobsen E; Curtit E; Boyle F; Harder Brix E; Brenner A; Crouzet L; Ferrario C; Muñoz-Mateu M; Arkenau HT; Iqbal N; Aithal S; Block M; Cold S; Cancel M; Hahn O; Poosarla T; Stringer-Reasor E; Colleoni M; Cameron D; Curigliano G; Siadak M; DeBusk K; Ramos J; Feng W; Gelmon K
Eur J Cancer; 2021 Aug; 153():223-233. PubMed ID: 34214937
[TBL] [Abstract][Full Text] [Related]
44. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
45. Intraoperative ultrasound guidance in breast-conserving surgery shows superiority in oncological outcome, long-term cosmetic and patient-reported outcomes: Final outcomes of a randomized controlled trial (COBALT).
Volders JH; Haloua MH; Krekel NM; Negenborn VL; Kolk RH; Lopes Cardozo AM; Bosch AM; de Widt-Levert LM; van der Veen H; Rijna H; Taets van Amerongen AH; Jóźwiak K; Meijer S; van den Tol MP
Eur J Surg Oncol; 2017 Apr; 43(4):649-657. PubMed ID: 27916314
[TBL] [Abstract][Full Text] [Related]
46. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
47. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Tripathy D; Rugo HS; Kaufman PA; Swain S; O'Shaughnessy J; Jahanzeb M; Mason G; Beattie M; Yoo B; Lai C; Masaquel A; Hurvitz S
BMC Cancer; 2014 May; 14():307. PubMed ID: 24885258
[TBL] [Abstract][Full Text] [Related]
48. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
49. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.
Gupta A; Khalid O; Moravek C; Lamkin A; Matrisian LM; Doss S; Denlinger CS; Coveler AL; Weekes CD; Roeland EJ; Hendifar AE; Nipp RD
Cancer Med; 2021 Oct; 10(20):7152-7161. PubMed ID: 34477302
[TBL] [Abstract][Full Text] [Related]
50. Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients.
Walker MS; Hasan M; Yim YM; Yu E; Stepanski EJ; Schwartzberg LS
Health Qual Life Outcomes; 2011 Jun; 9():46. PubMed ID: 21689425
[TBL] [Abstract][Full Text] [Related]
51. Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management.
Moons P; Norekvål TM; Arbelo E; Borregaard B; Casadei B; Cosyns B; Cowie MR; Fitzsimons D; Fraser AG; Jaarsma T; Kirchhof P; Mauri J; Mindham R; Sanders J; Schiele F; Torbica A; Zwisler AD
Eur Heart J; 2023 Sep; 44(36):3405-3422. PubMed ID: 37606064
[TBL] [Abstract][Full Text] [Related]
52. Home- or hospital-based monitoring to time frozen embryo transfer in the natural cycle? Patient-reported outcomes and experiences from the Antarctica-2 randomised controlled trial.
Zaat TR; de Bruin JP; Goddijn M; Visser J; Kaaijk EM; Lambalk CB; Groenewoud ER; van Wely M; Mol F
Hum Reprod; 2020 Apr; 35(4):866-875. PubMed ID: 32318722
[TBL] [Abstract][Full Text] [Related]
53. Long-term Patient-reported Outcomes Following Postmastectomy Breast Reconstruction: An 8-year Examination of 3268 Patients.
Nelson JA; Allen RJ; Polanco T; Shamsunder M; Patel AR; McCarthy CM; Matros E; Dayan JH; Disa JJ; Cordeiro PG; Mehrara BJ; Pusic AL
Ann Surg; 2019 Sep; 270(3):473-483. PubMed ID: 31356276
[TBL] [Abstract][Full Text] [Related]
54. Patient-reported outcome measures among breast cancer survivors: A cross-sectional comparison between Malaysia and high-income countries.
Rajaram N; Lim ZY; Song CV; Kaur R; Mohd Taib NA; Muhamad M; Ong WL; Schouwenburg M; See MH; Teo SH; Saunders C; Yip CH
Psychooncology; 2019 Jan; 28(1):147-153. PubMed ID: 30346074
[TBL] [Abstract][Full Text] [Related]
55. Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
Dos Santos M; Brachet PE; Chevreau C; Joly F
Cancer Treat Rev; 2017 Feb; 53():53-60. PubMed ID: 28073101
[TBL] [Abstract][Full Text] [Related]
56. Metastatic breast cancer patients' expectations and priorities for symptom improvement.
Tometich DB; Mosher CE; Hirsh AT; Rand KL; Johns SA; Matthias MS; Outcalt SD; Schneider BP; Mina L; Storniolo AMV; Newton EV; Miller KD
Support Care Cancer; 2018 Nov; 26(11):3781-3788. PubMed ID: 29736866
[TBL] [Abstract][Full Text] [Related]
57. Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action!
Joly F; McAlpine J; Nout R; Åvall-Lundqvist E; Shash E; Friedlander M;
Int J Gynecol Cancer; 2014 Nov; 24(9):1693-9. PubMed ID: 25340294
[TBL] [Abstract][Full Text] [Related]
58. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
[TBL] [Abstract][Full Text] [Related]
59. Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer.
Greer JA; Moy B; El-Jawahri A; Jackson VA; Kamdar M; Jacobsen J; Lindvall C; Shin JA; Rinaldi S; Carlson HA; Sousa A; Gallagher ER; Li Z; Moran S; Ruddy M; Anand MV; Carp JE; Temel JS
J Natl Compr Canc Netw; 2022 Feb; 20(2):136-143. PubMed ID: 35130492
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
